Streetbeat News

Equity Actions

FUTU

Analysts have mixed opinions on Futu Holdings (NASDAQ:FUTU), with recent ratings ranging from bullish to indifferent. The average 12-month price target is $63.12, up from the previous $52.40. Analysts from JP Morgan, UBS, Morgan Stanley, and Jefferies have provided updates, with price targets ranging from $50.00 to $71.50. Futu Holdings, an online broker, has shown strong financial performance with a revenue growth rate of 36.23%, a net margin of 41.18%, an ROE of 4.75%, an ROA of 1.09%, and a low debt-to-equity ratio of 0.22.

Portfolio Pulse from Benzinga Insights

January 17, 2024 | 1:00 pm

ETN

Eaton has appointed Olivier Leonetti as its new Executive Vice President and Chief Financial Officer. Leonetti, a current member of Eaton's board, will now take on an executive role within the company.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 12:35 pm

RNAZ

Transcode Therapeutics Inc has filed for an offering of up to 1.5 million shares of common stock, accompanied by warrants to purchase additional shares.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 12:14 pm

MCRB

Seres Therapeutics, Inc. (NASDAQ:MCRB) granted inducement equity grants to a new employee, consisting of 45,000 stock options and 22,500 restricted stock units (RSUs). This grant was made under Nasdaq Listing Rule 5635(c)(4) by the Compensation and Talent Committee of Seres' board of directors on January 10, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 12:10 pm

GFAI

Guardforce AI Co., Limited has appointed Yuting Zuo as its new Chief Financial Officer. This strategic move aims to strengthen the company's financial leadership as it continues to grow and expand its services.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 12:02 pm

PAG

Penske Automotive Group, Inc. (NYSE:PAG) has announced a 10% increase in its quarterly dividend to $0.87 per share, as approved by its Board of Directors. The company is a leading international transportation services provider and a top retailer of automotive and commercial trucks.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 12:01 pm

DTM

DT Midstream (NYSE:DTM) has been analyzed by 3 analysts, with mixed opinions ranging from bullish to bearish. The average 12-month price target is $56.33, with a high of $59.00 and a low of $53.00, reflecting a 2.03% decrease from the previous average. Analysts from Barclays, Wolfe Research, and Mizuho have provided updates, with Barclays raising its target to $59.00, Wolfe Research setting a target of $53.00, and Mizuho lowering its target to $57.00. DT Midstream operates in natural gas midstream services and has shown strong profitability with a net margin of 38.89%, but faces challenges with revenue decline, below-average ROE, and ROA.

Portfolio Pulse from Benzinga Insights

January 17, 2024 | 12:00 pm

RXRX

Analysts have provided mixed reviews on Recursion Pharmaceuticals (NASDAQ:RXRX) over the past three months, with 3 bullish and 1 indifferent rating. The average 12-month price target is $13.75, down from $14.00, with a high of $15.00 and a low of $10.00. Recent analyst actions include maintaining and lowering ratings and price targets. Recursion Pharmaceuticals is a clinical-stage biotech company with a strong market presence but faces challenges in revenue growth, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

January 17, 2024 | 12:00 pm

ADTN

Adtran (NASDAQ:ADTN) has received mixed analyst ratings over the past three months, with 2 bullish and 2 indifferent ratings. The average 12-month price target is now $8.25, down 17.5% from the previous $10.00. Analysts Ryan Koontz from Needham and Mike Genovese from Rosenblatt have made recent adjustments to their ratings and price targets. Adtran's financial health shows challenges with a -20.07% revenue decline, a net margin of -26.71%, and an ROE of -9.91%. However, the company has a prudent debt-to-equity ratio of 0.34. Analysts' ratings are based on various factors including future earnings and company updates.

Portfolio Pulse from Benzinga Insights

January 17, 2024 | 12:00 pm

ALB

Albemarle Corporation (NYSE:ALB) plans to reduce its capital expenditures for FY24 to $1.6B-$1.8B from $2.1B in FY23. The company aims to cut costs by $95M annually through workforce reduction and decreased contracted services spending. These measures are in response to changing market conditions, especially in the lithium value chain. Albemarle will focus on near-completion projects and defer others, expecting to save over $50M in 2024. A charge will be recorded in Q1 2024 related to these actions.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 11:50 am